Skip to main content

Table 1 Patient characteristics of all patients enrolled.

From: Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma

Total no. of patients (evaluable for response) 19 (18)
Sex (female/male) 11/8
Age, median (range) 63 (30–83)
Performance status (WHO)  
   0 1 (5%)
   1 12 (63%)
   2 6 (32%)
Tumor site  
   Gallbladder 3 (16%)
   Intrahepatic bile ducts 9 (47%)
   Extrahepatic bile ducts 7 (37%)
Site of metastasis  
   Liver 9 (47%)
   Lung 2 (11%)
   Lymph nodes 5 (26%)
   Peritoneum 2 (11%)
Recurrence after previous surgical resection 4 (21%)
Pre-treatment requiring stent or percutaneous transhepatic drainage because of obstructive jaundice 7 (37%)
Pre-treatment chemistries  
   Total bilirubin (mg/dl)  
Median 0,7
Range 0,3–2,3
   Gamma-glutamyltransferase (<66 U/La)  
Median 159
Range 34–671
   Aspartate aminotransferase (10–50 U/la)  
Median 29
Range 8–145
   CA19-9 (<32 U/mLa)  
Median 387
Range 4-1244000
  1. a normal levels